Everads Therapy

Executive Summary

Everads Therapy is an Israeli biotech startup pioneering a novel suprachoroidal delivery platform for retinal diseases. Founded in 2017, the company has developed a proprietary injector that enables rapid, extensive distribution of large-volume and large-particle therapeutics—including gene, cell, and antibody therapies—to the choroid and macula. This technology addresses a critical bottleneck in ocular drug delivery: achieving effective concentrations in the posterior segment while minimizing systemic exposure and repeated intravitreal injections. The platform's ability to accommodate high-viscosity formulations makes it particularly attractive for emerging gene therapies and biologics. Currently in Phase 1 clinical development, Everads has not publicly disclosed a lead candidate, but its platform is designed to be disease-agnostic and partner-friendly. The company is well-positioned to capitalize on the growing demand for advanced retinal therapies, with the global retinal disease market projected to exceed $20 billion by 2030. Key upcoming catalysts include initial proof-of-concept data from ongoing Phase 1/2 studies, potential strategic partnerships with large pharmaceutical companies seeking delivery solutions for their gene and cell therapy pipelines, and possible IND or regulatory designations that could accelerate development. While still early-stage, Everads' innovative approach and experienced team warrant close monitoring.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 clinical data readout for lead candidate50% success
• Q2 2027Strategic partnership or licensing agreement for platform use40% success
• Q3 2027FDA IND acceptance for a gene therapy program utilizing the platform35% success